首页> 外文期刊>Malaria research and treatment >Formulation and Particle Size Reduction Improve Bioavailability of Poorly Water-Soluble Compounds with Antimalarial Activity
【24h】

Formulation and Particle Size Reduction Improve Bioavailability of Poorly Water-Soluble Compounds with Antimalarial Activity

机译:配方和减小粒径可提高具有抗疟疾活性的水溶性差的化合物的生物利用度

获取原文
           

摘要

Decoquinate (DQ) is highly effective at killing malaria parasitesin vitro; however, it is extremely insoluble in water. In this study, solid dispersion method was used for DQ formulation which created a suitable physical form of DQ in aqueous phase for particle manipulation. Among many polymers and surfactants tested, polyvinylpyrrolidone 10, a polymer, and L-α-phosphatidylcholine or polysorbate, two surfactants, were chosen as DQ formulation components. The formulation particles were reduced to a mean size between 200 to 400 nm, which was stable in aqueous medium for at least three weeks. Pharmacokinetic (PK) studies showed that compared to DQ microparticle suspension, a nanoparticle formulation orally dosed to mice showed a 14.47-fold increase in area under the curve (AUC) of DQ plasma concentration and a 4.53-fold increase in AUC of DQ liver distribution. WR 299666, a poorly water-soluble compound with antimalarial activity, was also tested and successfully made into nanoparticle formulation without undergoing solid dispersion procedure. We concluded that nanoparticles generated by using appropriate formulation components and sufficient particle size reduction significantly increased the bioavailability of DQ and could potentially turn this antimalarial agent to a therapeutic drug.
机译:Decoquinate(DQ)在体外杀死疟原虫方面非常有效;但是,它极难溶于水。在这项研究中,DQ配方采用了固体分散法,该方法在水相中形成了合适的DQ物理形式用于颗粒处理。在测试的许多聚合物和表面活性剂中,聚乙烯吡咯烷酮10(一种聚合物)和L-α-磷脂酰胆碱或聚山梨酸酯被选为DQ配方组分。将制剂颗粒减小至200至400nm之间的平均尺寸,其在水性介质中稳定至少三周。药代动力学(PK)研究表明,与DQ微粒悬浮液相比,口服给予小鼠的纳米颗粒制剂显示DQ血浆浓度曲线下面积(AUC)增加了14.47倍,DQ肝脏分布的AUC增加了4.53倍。还测试了WR 299666,这是一种具有抗疟疾活性的水溶性差的化合物,无需经过固体分散程序即可成功地制成纳米颗粒制剂。我们得出的结论是,通过使用适当的制剂组分和足够的粒径减小而产生的纳米颗粒显着提高了DQ的生物利用度,并且有可能将该抗疟剂转化为治疗药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号